Metformin is used to treat type 2 diabetes, polycystic ovary syndrome associated infertility, and gestational diabetes. This study aims to evaluate the safety of metformin in early pregnancy.
Introduction
Metformin (N,N-dimethylbiguanide) is a biguanide hypoglycaemic agent exerting its therapeutic action primarily by reducing hepatic glucose production and, to a lesser extent, by improving glucose uptake and use by peripheral tissues [1] . It is the most widely used first line treatment for type 2 diabetes in the general population [2] . It does not induce hypoglycaemia or weight gain and is usually well tolerated [2] . Metformin is also an alternative to insulin therapy for gestational diabetes mellitus (GDM) [3] [4] [5] [6] . Besides its use for diabetes, metformin is an effective treatment for polycystic ovary syndrome (PCOS) associated infertility.
Metformin controls glycaemia in pregnant women with GDM, and it has been shown to prevent adverse maternal and neonatal outcomes associated with hyperglycaemia [7] . However, evidence regarding its safety and effectiveness to achieve glycaemic targets in the management of type 2 diabetes in pregnancy is limited [8, 9] . Moreover, since metformin, like most other drugs, crosses the placental barrier [10] , embryological and fetal risks need to be considered when exposure occurs early in pregnancy. Animal studies did not find metformin to have a teratogenic effect [11, 12] . In humans, the few studies that assessed the risk of congenital anomalies showed no evidence of any major teratogenic effect [13, 14] . Less is known regarding the potential risk of miscarriages and stillbirths. Further studies are warranted to confirm the safety of metformin when used in early pregnancy.
To better characterize the safety of metformin use early in pregnancy we conducted an observational cohort study and evaluated the risk of birth defects and pregnancy losses after first trimester exposure to metformin. We took advantage of the several potential indications to disentangle the effect of metformin from the known effects of diabetes on pregnancy outcomes.
Methods

Study design and participants
Twelve participating Teratology Information Services (TIS), members of the European Network of Teratology Information Services (ENTIS), and 17 French pharmacovigilance centres collected data for this multicenter, prospective, observational cohort study. The TIS provide information on the safety and risks of medications before and during pregnancy [15] . For each patient seeking counselling directly or through their healthcare provider, structured information on the exposure (medication, time of exposure, dose), maternal demographics, as well as medical and obstetric history is collected in order to study drug safety with respect to developmental toxicity [15, 16] . Enrolment occurs at the time of first contact, which can be at any time during pregnancy. Follow-up information is gathered after the estimated date of birth, with inquiry as to pregnancy outcome, gestational age at delivery, birth weight, congenital anomalies and neonatal complications through structured telephone interviews and/or mailed questionnaires sent to the mothers or their healthcare providers [15] . Women are enrolled using the same methodology, as all ENTIS members use similar documentation and follow-up methodology [17] [18] [19] . Pregnant women considered as lost to follow-up were not included in the study (overall rate of loss to follow-up across centres was 10-30% and is expected to be similar in both exposed and reference groups as they were matched for centre). Gestational age throughout pregnancy was estimated using last menstrual period (LMP) or first trimester ultrasound dating, and provided in completed weeks.
The ENTIS scientific committee approved the study protocol. This observational study contained only anonymous health data, so did not require ethics committee approval in most participating centres; otherwise, approval was received from appropriate authorities.
Exposed and reference groups
Eligible pregnant women for the exposure group were those using metformin (Anatomical Therapeutic Chemical A10BA02) at any time during pregnancy (i.e. any time between conception to week 42 after LMP). A subset of randomly selected pregnant women matched to the exposed women with a ratio of 1:1 according to centre, year of counselling, maternal age, and week of gestational age at enrolment was used as reference group. Eligible pregnant women for the reference group were those that at no time during pregnancy used metformin, insulin or any other hypoglycaemic agent.
For the primary outcomes (pregnancy losses and major birth defects), we considered as exposed only women on metformin during the first trimester of pregnancy. For secondary outcomes expected to have a period of susceptibility beyond the first trimester (i.e., delivery mode, preterm birth, birth weight and macrosomia), we considered metformin exposure after the first trimester of pregnancy. The same unexposed reference group was used for primary and secondary outcomes. Within the exposed group we distinguished two categories, women on metformin with a pre-gestational diabetes diagnosis and women on metformin without this indication.
Women were excluded from both groups if they were (a) exposed to any of the following known major teratogens or major fetotoxicants: acitretin, isotretinoin, mycophenolate, thalidomide, valproic acid, angiotensin-II receptor blockers (only when used in second or third trimester), ACE inhibitors 
Outcomes
The primary outcomes of interest were the risk of major birth defects (MBD) and the risk of spontaneous pregnancy losses including abortions (i.e. pregnancy loss before 20 completed weeks of pregnancy) (SAB) and stillbirths (i.e. pregnancy loss after 20 completed weeks of pregnancy). Birth defects were classified as major or minor by two independent specialists blinded to exposure using two standard classifications (DB, EA) [20, 21] . In case of disagreement, consensus was reached through discussion. Estimation of MBD and pregnancy loss risks was restricted to participants enrolled before the end of the first trimester. Estimation of MBD was restricted to participants with live births or with known results after appropriate pathology exam on the product of fetal loss in case of pregnancy losses (i.e. known birth defect outcome) in both exposed and reference groups.
Secondary outcomes were the risk of elective pregnancy termination (ETOP), medical pregnancy termination (MTOP) -a procedure performed when the pregnancy endangers the mother's health or when the fetus has a condition incompatible with normal life -as well as gestational weeks at birth, birth weight, and delivery mode. Neonatal outcomes such as preterm birth (<37 weeks of gestational age), low birth weight (≤2500 g) (LBW), and macrosomia (≥4500 g) were also assessed as secondary endpoints. This latter assessment was restricted to a subset of patients with available information for these outcomes.
Statistical analysis
The proportion of MBD for each exposure group and the 95% confidence interval (95% CI) were estimated using a binomial exact method. The association between metformin exposure and the risk of MBD and other complications later in pregnancy was evaluated using multivariate logistic regression analysis to estimate odds ratios (OR) with 95% CI and adjust for confounding factors [maternal age, pre-pregnancy body mass index (BMI), hypertension, use of other medications and study centre]. BMI was categorized (<26, 26-30,>30), with an additional category for the missing values.
Spontaneous losses (SAB and stillbirths) and pregnancy terminations (ETOP and MTOP) were considered competing risks and their frequency is presented as cumulative incidence functions. Women were followed from the gestational age at enrolment (start date) [22] . While pregnancy outcome was available for all participants, gestational age at pregnancy outcome was missing for about 6% of the women. These missing values were imputed according to the observed distribution of gestational age at pregnancy outcome for the three possible pregnancy outcomes (i.e., losses, terminations and live births) and within exposure category (diabetes exposed to metformin, non-diabetes exposed to metformin, control group), and conditionally on the imputed gestational age at pregnancy outcome being larger than the gestational age at which the women entered the study. The imputation process was repeated 100 times and the cumulative incidences obtained were averaged over these 100 analyses. Besides calculating cumulative incidences, a Cox regression model was used to estimate the adjusted hazard ratios (HR adj ) of these pregnancy outcomes associated with metformin exposure during the first trimester [23] .
Statistical analyses were performed using SAS version 9.4 (AS Institute, Cary, NC) and R version 3.2.1.
Evaluation of confounding factors
Since very few women in the unexposed group would have the indications for metformin, confounding by pre-gestational diabetes was assessed by stratification of the exposed group based on the presence or absence of pre-gestational diabetes diagnosis, and on severity criteria defined as the presence of any abnormal glucose test (glycated haemoglobin HbA1c/fasting blood glucose test/2 h oral glucose tolerance test/other) or concomitant use of other oral diabetic drugs or insulin. Important imbalances between the metformin group and the reference group were considered in the regression models.
Results
Cohort size, exposure and maternal characteristics
Between 1993 and 2015, the number of enrolled pregnant women was 471 in the metformin exposed group and 479 Table 1 , important differences between the two groups were observed. More patients in the metformin group had a BMI above 30 (23% vs. 4%), pre-gestational diabetes (57% vs. <1%), hypertension (13% vs. 2%), exposure to >1 medication (77% vs. 44%), >1 prior delivery (33% vs. 22%) and ≥1 previous SAB (22% vs. 16%).
Birth defects
The proportion of offspring with birth defects is presented in Table 2 . Among women enrolled and exposed to metformin during the first trimester, 392 (84%) pregnancies were live births or pregnancy losses with known results after appropriate pathology exam on the product of fetal loss (i.e. with available information on the presence of birth defects); 14 of the 79 pregnancy losses had known results after pathology exam. The corresponding number of informative pregnancies in the reference group was 431 (83%); 10 of the 58 pregnancy losses had known results after appropriate pathology exam on the product of fetal loss.
The risk of MBD without chromosomal or genetic origin was higher in the group exposed to metformin during the first trimester (5%; 20/392) than in the matched reference group (2%; 9/431). Similar trends were observed for minor BD (3% vs. 2%) and cardiac BD (2% vs. 1%). The risk of BD with chromosomal or genetic origin was similar in both groups (4/392 vs. 5/431). After adjustment for maternal age, BMI, maternal hypertension, use of >1 medication and centre, the OR for MBD was 1.70 (95% CI 0.70-4.38) and for cardiac BD specifically was 1.53 (95% CI 0.43-5.72). Further adjustment for indication yielded an OR for MBD of 0.80 (95% CI 0.19-2.77). However, as very few unexposed women had the indications to explore the impact of pre-gestational diabetes in the association, we stratified the exposed group by indication.
As shown in Figure 1 , the risk of MBD varied based on the presence of pre-gestational diabetes, as well as diabetes severity criteria. The risk of MBD in patients exposed to metformin without pre-gestational diabetes was 2% (3/173) and with a diagnosis of pre-gestational diabetes it was 8% (17/219). Within the latter, the risk of MBD in patients having at least one severity criterion for diabetes was 10% (14/140). For this analysis, since adjustment for other covariates did not change the results, we present only the crude ORs. Compared to the unexposed reference, the OR for metformin without diabetes was 0.83 (95% CI 0.18-2.81) and for metformin with diabetes was 3.95 (95% CI 1.77-9.41). Details on infants with MBD in the metformin and reference group are provided in Table S1 (supplemental material).
Spontaneous abortion and stillbirth
The mean gestational age at enrolment in the pregnancies included in this analysis (i.e. early enrolees) was 9 weeks for the metformin group and 8 weeks for the reference group. The cumulative risk of pregnancy losses was 10.8% in the reference group and 21% in women exposed to metformin early in pregnancy. The crude HR was 1.92 (95% CI 1.17-3.15) and the adjusted HR was 1.57 (95% CI 0.90-2.74). Within the exposed group, the risk of pregnancy loss was 24% among women with pre-gestational diabetes and 17% when metformin was used for other indications (Figure 2 ). Compared to the reference, the crude HR was 2.51 (95% CI 1.44-4.36) for women with pre-gestational diabetes and 1.38 (95% CI 0.74-2.59) for other indications.
Other outcomes
Details for other pregnancy and neonatal outcomes are presented in Table 3 . The risk of ETOP was lower in the group exposed to metformin during the first trimester (2%; 9/458) than in the matched reference group (4%; 20/471). Inverse trends were observed for MTOP (3%; 12/458 vs. 1%; 6/471). The risk of preterm birth was higher in the metformin group (19%; 71/379 vs. 6%; 25/421 with OR crude 3.63; 95% CI 2.27-5.97). After adjustment for maternal age, BMI, maternal hypertension, use of >1 medication and centre, the OR for preterm was OR adj 3.19 (95% CI 1.90-5.43). Within the exposed to metformin group, the risk of preterm was 25% (51/208) among women with pre-gestational diabetes and 12% (20/170) when metformin was used for other Table 2 Risk of birth defects in pregnancies exposed to metformin during the first trimester compared to the matched unexposed reference group. Metformin study from European Teratology Information Services (TIS) 1993-2015 When the metformin group was split into patients with a first trimester exposure only (discontinuers) and those with first trimester exposure and at least some second and third trimester exposure (continuers), and restricted to patients with available information for the assessed outcomes, the risk of preterm birth was higher in the continuers group (32%; 33/102 vs. 15%; 36/241 with OR crude 2.70; 95% CI 1.58-4.64). After adjustment for maternal age, pregestational diabetes, BMI, maternal hypertension, use of >1 medication and centre, the OR for preterm was 2.41 (95% CI 1.35-4.29). The risk of macrosomia in the continuers group was 5% (5/102) vs. 3% (8/241) with OR crude 1.52 (95% CI 0.45-4.68). After adjustment, the OR for macrosomia was 1.02 (95% CI 0.28-3.42). The risk of assisted delivery in the continuers group was 72% (5/102) vs. 61% (146/241) with OR crude (1.55; 95% CI 0.95-2.57). After adjustment, the OR for assisted delivery remained the same (OR adj 1.50; 95% CI 0.90-2.52). Detailed information is presented in Table S2 (supplemental material).
Discussion
This study prospectively evaluated 458 pregnancies exposed to metformin during pregnancy and revealed an increased risk for major birth defects and pregnancy losses in women exposed to metformin during specific periods of susceptibility compared to an unexposed population. However, the restriction of this association to women on metformin for their pre-gestational diabetes suggests a significant confounding role of this indication.
In our study, reflecting the general population, a large proportion of the patients in the metformin group had a diagnosis of diabetes before pregnancy (63%) compared to those unexposed (<1%). Moreover, unsurprisingly, the frequency Figure 1 Risk of major birth defects stratified by exposure to metformin, indication and severity of diabetes Figure 2 Cumulative incidence of pregnancy losses and terminations stratified by exposure to metformin and indication of other associated risk factors (e.g., obesity, hypertension and hyperlipidaemia) was also increased in the metformin group [24] . These differences affect the risk of adverse pregnancy outcomes and therefore the comparability of the groups. Since adequate adjustment for indication was not possible, we based our assessment of confounding by pregestational diabetes in the informal comparison with pregnancies exposed to metformin for other indications. As PCOS and some of the indications described in the other indications group have also been associated with insulin resistance, confounding by glucose management was probably not completely controlled. Thus, future studies should compare metformin exposed pregnancies with women with the same indication and treated with alternative therapies, for example those on insulin.
These results are in accordance with previous studies [13, 14, [25] [26] [27] . In women with poorly controlled pregestational diabetes, the risk of MBD has been shown to be 5-10% in live births [28] . The risks in our cohort were similar, with 8% of MBD in pregnancies with pre-gestational diabetes; increasing to 10.0% when the mother had at least one severity criterion for diabetes. However, the risk of MBD was similar in the reference group of patients not exposed to metformin (2.1%) and in those exposed to metformin for indications other than pre-gestational diabetes (1.7%). Our findings suggest that the observed association between metformin and MBD could be explained by confounding by the underlying diabetes.
Whether diabetes increases a woman's risk of having a spontaneous abortion has been under debate for a long time [29] . Overall studies suggest that poor metabolic control may be at increased risk of spontaneous abortion [25, [29] [30] [31] [32] [33] [34] . Similarly, in our study the risk of pregnancy losses was higher (21%) in the group exposed to metformin with a diagnosis of pre-gestational diabetes than in the metformin exposed group without pre-gestational diabetes (17%). The higher risk estimate observed in the metformin exposed without pre-gestational diabetes group, when compared to the reference group (10.8%), can probably be explained by the higher prevalence of PCOS reported in this group, a condition associated with higher spontaneous abortion rates [35] , as well as the other diagnostics associated with insulin resistance.
The elevated risk for minor BD and cardiac BD in women on metformin is also likely explained by other baseline characteristics including obesity and hypertension [36, 37] . The association between metformin and cardiac defects attenuated after adjustment for these risk factors. As minor BD are largely underreported to TISes, the increased risk could also be partially explained by a differential identification through closer postnatal monitoring of women with diabetes in the metformin group.
Besides the increased risk of MBD and SAB, diabetes in pregnancy is associated with other risks to the woman and to the developing fetus [5] . Consistent with previous findings, we observed an increased risk of preterm birth and assisted deliveries in patients with at least some metformin use in the second and third trimester. The association attenuated for preterm after adjustment or when restricting to women with pre-gestational diabetes diagnosis, but not for assisted deliveries. Larger studies have shown an increased risk of caesarean section with maternal pre-existing diabetes and obesity of similar magnitude [38] . In our study, adjusting for these covariates has not attenuated the association, suggesting that other factors are involved. Furthermore, interpretation of the results should be done cautiously as the sample size was small after restriction.
We observed an elevated proportion of women discontinuing the treatment during the first trimester (73%). This finding can partly be explained by the fact that metformin is often discontinued once the pregnancy is started when used for PCOS (12% of the patients were using metformin for PCOS) or because of a lack of adequate glucose control. The large proportion of discontinuing patients observed probably also reflects the concern regarding safety and supports the need for making these results available to women and prescribers.
The strengths and limitations of prospective observational pregnancy cohorts studies based on TIS data have been discussed in detail previously [16] . Although this is the largest study published to date, the sample size is still too small and follow-up duration too short to reach a final assessment on the safety and risks associated with the use of metformin in pregnancy. For example, it is important to note that the sample size was sufficient to detect only a fourfold increase in the risk of cardiac BD, given a baseline risk in the general population of 1% with a power of 80% and Type I error of 0.05. The main limitation of this study is the absence of a reference group composed of women treated for similar conditions. A reference group with patients taking insulin was unfortunately not available in the TIS cohort as this treatment is considered safe for use in pregnancy, thus only a few patients or their healthcare provider seek safety information on insulin. Although we cannot completely rule out any bias, the prospective approach of our study with similar procedures of data ascertainment across cohorts makes a substantial bias of exposure or outcome misclassification less likely. Finally, findings from this study might not be generalizable to other populations as the biological relations studied could be affected by characteristics of the studied population (i.e. medium-and high-level educated women tend to be overrepresented among TIS enquirers [39] ) that differ from the general population. It remains, however, an important population to study in its own right.
In conclusion, pregnant women with pre-gestational diabetes on metformin are at an increased risk for multiple adverse pregnancy outcomes. However, this risk appears to be due to the underlying diabetes, with no indication of a teratogenic or abortifacient effect of metformin itself. Future studies comparing metformin exposed pregnancies with women with the same indication and treated with alternative therapies, e.g., on insulin are warranted.
